Home>Publications>Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews
Anthony L, Horsch D, Ervin C, Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews. Poster presented at the 8th Symposium of the North American Neuroendocrine Tumor Society; October 15, 2015. Austin, TX.
The power of knowledge. The value of understanding.
Steeped in a tradition of rigor and process, we maintain a legacy of setting the scientific standards within our industry. We employ the right approaches and proven research practices to analyze evidence and draw meaningful insights. Our uncompromisingly ethical and objective researchers ensure that results will hold up to scrutiny and reveal the benefits, risks, value and potential of your products. Learn more.